PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 ...
The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. The Food and Drug Administration (FDA) has approved Aphexda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results